Insider Sale by Kestra Medical’s General Counsel
Traci S. Umberger, who serves as General Counsel, Chief Administrative Officer and a Director of Kestra Medical Technologies Ltd (ticker KMTS), disposed of a total of 22,229 common shares between July 30 2026 and August 3 2026, generating gross proceeds of $512,791. The first transaction on July 30 2026 involved 5,887 shares sold at a weighted‑average price of $22.7437 per share, with individual trade prices ranging from $22.2400 to $23.1700. The following day, July 31 2026, she sold an additional 8,752 shares at a weighted‑average price of $22.6048, the share price varying between $22.1700 and $22.9200. The final sale on August 3 2026 comprised 7,590 shares at a weighted‑average price of $23.8553, with prices between $23.6500 and $24.2800. All three sales were classified as nondiscretionary, undertaken to satisfy tax‑withholding obligations arising from the vesting and settlement of restricted stock units.
After completing these transactions, Ms. Umberger’s direct beneficial ownership stands at 199,405 Kestra common shares. At the time of reporting, Kestra’s share price was $28.02, reflecting a 75 % increase over the prior year and positioned near its 52‑week high of $30.00. The company’s market capitalization was reported at approximately $1.63 billion.
Recent Operational and Analyst Updates
In its fiscal fourth quarter of 2026, Kestra Medical Technologies reported revenue of $28.64 million, representing a 66 % year‑over‑year increase. Despite the top‑line growth, the company posted an adjusted loss of $0.67 per share, missing the consensus forecast of a $0.58 loss per share. The earnings miss was accompanied by analyst actions: Stifel reiterated a Buy rating with a price target of $30.00, citing strong growth and record prescriptions for the ASSURE wearable cardioverter‑defibrillator; Wolfe Research also raised its price target to $30.00, highlighting better‑than‑expected execution; JPMorgan initiated coverage with an Overweight rating, emphasizing the potential of the ASSURE device in a market historically dominated by a single incumbent; and Oppenheimer began coverage with a Perform rating, noting Kestra’s expanding market share and the sizable total addressable market for wearable cardiac devices.
Market Context
The insider sales occurred amid a period of significant share price appreciation and heightened analyst interest, underscoring the relevance of the transactions for investors monitoring insider activity and the company’s growth trajectory.